Depression in patients with heart failure: Clinical implications and management

Pharmacotherapy

Volumn 29, Issue 1, 2009, Pages 49-63

  Watson, Kristin ^a,b   Summers, Kelly M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NONE   (United States)

Author keywords

Antidepressants; Defibrillators; Depression; Heart failure; adrenergic antagonists

Indexed keywords

AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CITALOPRAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOXETINE; METOPROLOL SUCCINATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALCOHOL ABUSE; ANAMNESIS; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EXERCISE; FATIGUE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAXATION TRAINING; REVIEW; SCREENING; SEXUAL DYSFUNCTION; SIDE EFFECT; STRESS MANAGEMENT; SYSTOLIC BLOOD PRESSURE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; WEAKNESS; WEIGHT GAIN;

EID: 59949104666     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.1.49     Document Type: Review

References (105)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2008;117:e25-146.
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2007;115:e69-171. (Erratum in Circulation 2007;115:3.172.)
3. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581-7.
4. Chin MH, Goldman L. Factors contributing to hospitalization of patients with congestive heart failure. Am J Public Health 1997;87:643-8.
5. Fulop G, Strain JJ, Stettin G. Congestive heart failure and depression in older adults: clinical course and health services use 6 months after hospitalization. Psychosomatics 2003;44:367-73.
6. Faris R, Purcell H, Henein MY, Coats AJ. Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure. Eur J Heart Fail 2002;4:541-51.
7. Carels RA. The association between disease severity, functional status, depression and daily quality of life in congestive heart failure patients. Qual Life Res 2004; 13:63-72.
8. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849-56.
9. de Denus S, Spinler SA, Jessup M, Kao A. History of depression as a predictor of adverse outcomes in patients hospitalized for decompensated heart failure. Pharmacotherapy 2004;24:1306-10.
10. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527-37.
11. Office of the Surgeon General. Mental health: A report of the surgeon general. Available from www.surgeongeneral.gov. Accessed April 15, 2008.
12. Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007;167:367-73.
13. Heo S, Moser DK, Lennie TA, Zambroski CH, Chung ML. A comparison of health-related quality of life between older adults with heart failure and healthy older adults. Heart Lung 2007;36:16-24.
14. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the medical outcomes study. JAMA 1989;262:907-13. (Erratum in JAMA 1989;262:2542.)
15. Gottlieb SS, Khatta M, Friedmann E, et al. The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol 2004;43:1542-9.
16. Rumsfeld JS, Havranek E, Masoudi FA, et al. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol 2003;42:1811-17.
17. Sullivan M, Simon G, Spertus J, Russo J. Depression-related costs in heart failure care. Arch Intern Med 2002;162:1860-6.
18. Segal ZV, Whitney DK, Lam RW, for the CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry 2001;46(suppl 1):S29-37.
19. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(4 suppl):1-45.
20. Mann JJ. The medical management of depression. N Engl J Med 2005;353:1819-34.
21. Unutzer J. Clinical practice: late-life depression. N Engl J Med 2007;357:2269-76.
22. Lesperance F, Frasure-Smith N, Laliberte MA, et al. An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Can J Psychiatry 2003;48:695-701.
23. Gottlieb SS, Kop WJ, Thomas SA, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J 2007;153:868-73.
24. van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly: problem and possible solutions. Int J Cardiol 2008;125:203-8.
25. . Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA 2003;289:3106-16.
26. Frasure-Smith N, Lesperance F, Gravel G, Masson A, Juneau M, Bourassa MG. Long-term survival differences among low- anxious, high-anxious and repressive copers enrolled in the Montreal heart attack readjustment trial. Psychosom Med 2002;64:571-9.
27. Alves TC, Rays J, Telles RM, et al. Effects of antidepressant treatment on cognitive performance in elderly subjects with heart failure and comorbid major depression: an exploratory study. Psychosomatics 2007;48:22-30.
28. van der Wal MH, Jaarsma T, Moser DK, Veeger NJ, van Gilst WH, van Veldhuisen DJ. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J 2006;27:434-40.
29. Lane DA, Chong AY, Lip GY. Psychological interventions for depression in heart failure. Cochrane Database Syst Rev 2005;(1):CD003329.
30. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9. (Erratum in JAMA 2002;288:1720.)
31. . Honig A, Kuyper AM, Schene AH, et al. Treatment of post- myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 2007;69:606-13.
32. van den Brink RH, van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial infarction and depression-intervention trial (MIND-IT). Am HeartJ 2002;144:219-25.
33. Goldston K, Baillie AJ. Depression and coronary heart disease: a review of the epidemiological evidence, explanatory mechanisms and management approaches. Clin Psychol Rev 2008;28:288-306.
34. Paraskevaidis I, Parissis JT, Fountoulaki K, Filippatos G, Kremastinos D. Selective serotonin re-uptake inhibitors for the treatment of depression in coronary artery disease and chronic heart failure: evidence for pleiotropic effects. Cardiovasc Hematol Agents Med Chem 2006;4:361-7.
35. Jiang W, Davidson JR. Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005;150:871-81.
36. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-8.
37. Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007;120:525-30.
38. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the sertraline antidepressant heart attack randomized trial (SADHART) platelet substudy. Circulation 2003;108:939-44.
39. Pollack MH, Rosenbaum JF, Cassem NH. Propranolol and depression revisited: three cases and a review. J Nerv Ment Dis 1985;173:118-19.
40. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57:875-82.
41. Schins A, Hamulyak K, Scharpe S, et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sci 2004;76:637-50.
42. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007;190:460-6.
43. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:660-5.
44. Roose SP, Glassman AH, Giardina EG, Johnson LL, Walsh BT, Bigger JT Jr. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987;7:247-51.
45. Giardina EG, Johnson LL, Vita J, Bigger JT Jr, Brem RF. Effect of imipramine and nortriptyline on left ventricular function and blood pressure in patients treated for arrhythmias. Am Heart J 1985;109:992-8.
46. Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983;250:1997-2001.
47. Roose SP, Glassman AH, Giardina EG, et al. Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986;256:3253-7.
48. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT Jr. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987;44:273-5.
49. Alvarez W Jr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 2003;23:754-71.
50. Himmelhoch JM, Schechtman K, Auchenbach R. The role of trazodone in the treatment of depressed cardiac patients. Psychopathology 1984;17(suppl 2):51-63.
51. . Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006;14:796-802.
52. Oslin DW, Ten Have TR, Streim JE, et al. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003;64:875-82.
53. Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006;295:2874-81.
54. Williams JW Jr, Noel PH, Cordes JA, Ramirez G, Pignone M. Is this patient clinically depressed? JAMA 2002;287:1160-70.
55. Rees K, Bennett P, West R, Davey SG, Ebrahim S. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2004;(2):CD002902.
56. Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 2001;322:763-7.
57. McKelvie RS, Teo KK, Roberts R, et al. Effects of exercise training in patients with heart failure: the exercise rehabilitation trial (EXERT). Am Heart J 2002;144:23-30.
58. Kostis JB, Rosen RC, Cosgrove NM, Shindler DM, Wilson AC. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. Chest 1994;106: 996-1001.
59. Yu DS, Lee DT, Woo J. Effects of relaxation therapy on psychologic distress and symptom status in older Chinese patients with heart failure. J Psychosom Res 2007;62:427-37.
60. Yu DS, Lee DT, Woo J, Hui E. Non-pharmacological interventions in older people with heart failure: effects of exercise training and relaxation therapy. Gerontology 2007;53:74-81.
61. . Chang BH, Hendricks A, Zhao Y, Rothendler JA, LoCastro JS, Slawsky MT. A relaxation response randomized trial on patients with chronic heart failure. J Cardiopulm Rehabil 2005;25:149-57.
62. Luskin F, Reitz M, Newell K, Quinn TG, Haskell W. A controlled pilot study of stress management training of elderly patients with congestive heart failure. Prev Cardiol 2002;5:168-72.
63. Barrow DE, Bedford A, Ives G, O'Toole L, Channer KS. An evaluation of the effects of tai chi chuan and chi kung training in patients with symptomatic heart failure: a randomised controlled pilot study. Postgrad Med J 2007;83:717-21.
64. Jayadevappa R, Johnson JC, Bloom BS, et al. Effectiveness of transcendental meditation on functional capacity and quality of life of African Americans with congestive heart failure: a randomized control study. Ethn Dis 2007;17:72-7.
65. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007;357:1939-45.
66. Solimene MC. Electroconvulsive therapy and the heart [letter]. Int J Cardiol 2007;114:103.
67. Fuenmayor AJ, el Fakih Y, Moreno J, Fuenmayor AM. Effects of electroconvulsive therapy on cardiac function in patients without heart disease. Cardiology 1997;88:254-7.
68. Artinian NT, Artinian CG, Saunders MM. Identifying and treating depression in patients with heart failure. J Cardiovasc Nurs 2004;19:S47-56.
69. Koenig HG. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 1998;20:29-43.
70. Turvey CL, Klein DM, Pies CJ. Depression, physical impairment, and treatment of depression in chronic heart failure. J Cardiovasc Nurs 2006;21:178-85.
71. Havranek EP, Spertus JA, Masoudi FA, Jones PG, Rumsfeld JS. Predictors of the onset of depressive symptoms in patients with heart failure. J Am Coll Cardiol 2004;44:2333-8.
72. Schrader G, Cheok F, Hordacre AL, Guiver N. Predictors of depression three months after cardiac hospitalization. Psychosom Med 2004;66:514-20.
73. Koenig HG. Depression outcome in inpatients with congestive heart failure. Arch Intern Med 2006;166:991-6.
74. U.S. Preventive Services Task Force. Screening for depression: recommendations and rationale. Ann Intern Med 2002;136:760-4.
75. Ackermann RT, Rosenman MB, Downs SM, et al. Telephonic case-finding of major depression in a Medicaid chronic disease management program for diabetes and heart failure. Gen Hosp Psychiatry 2005;27:338-43.
76. Poole NA, Morgan JF. Validity and reliability of the hospital anxiety and depression scale in a hypertrophic cardiomyopathy clinic: the HADS in a cardiomyopathy population. Gen Hosp Psychiatry 2006;28:55-8.
77. Hilton TM, Parker G, McDonald S, et al. A validation study of two brief measures of depression in the cardiac population: the DMI-10 and DMI-18. Psychosomatics 2006;47:129-35.
78. Wise FM, Harris DW, Carter LM. Validation of the cardiac depression scale in a cardiac rehabilitation population. J Psychosom Res 2006;60:177-83.
79. McManus D, Pipkin SS, Whooley MA. Screening for depression in patients with coronary heart disease: data from the heart and soul study. Am J Cardiol 2005;96:1076-81.
80. Bardy GH, Lee KL, Mark DB, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. (Erratum in N Engl J Med 2005;352:2146.)
81. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease: multicenter unsustained tachycardia trial investigators. N Engl J Med 1999;341:1882-90. (Erratum in N Engl J Med 2000;342:1300.)
82. Heller SS, Ormont MA, Lidagoster L, Sciacca RR, Steinberg S. Psychosocial outcome after ICD implantation: a current perspective. Pacing Clin Electrophysiol 1998;21:1207-15.
83. Kamphuis HC, de Leeuw JR, Derksen R, Hauer RN, Winnubst JA. Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery-a prospective study. Europace 2003;5:381-9.
84. Lemon J, Edelman S, Kirkness A. Avoidance behaviors in patients with implantable cardioverter defibrillators. Heart Lung 2004;33:176-82.
85. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-94.
86. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian implantable defibrillator study (CIDS). Am Heart J 2002;144:282-9.
87. Namerow PB, Firth BR, Heywood GM, Windle JR, Parides MK. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG patch trial. Pacing Clin Electrophysiol 1999;22: 1305-13.
88. Carney RM, Freedland KE, Rich MW, Smith LJ, Jaffe AS. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. AmJ Med 1993;95:23-8.
89. Whang W, Albert CM, Sears SF Jr, et al. Depression as a predictor for appropriate shocks among patients with implantable cardioverter- defibrillators: results from the triggers of ventricular arrhythmias (TOVA) study. J Am Coll Cardiol 2005;45:1090-5.
90. Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the antiarrhythmics versus implantable defibrillators (AVID) trial. J Cardiovasc Electrophysiol 2003;14:940-8.
91. Rosenqvist M, Beyer T, Block M, den Dulk K, Minten J, Lindemans F, for the European 7219 Jewel ICD Investigators. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. Circulation 1998;98:663-70. (Erratum in Circulation 1998;98:2647.)
92. Kohn CS, Petrucci RJ, Baessler C, Soto DM, Movsowitz C. The effect of psychological intervention on patients' long- term adjustment to the ICD: a prospective study. Pacing Clin Electrophysiol 2000;23:450-6.
93. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235. (Erratum in Circulation 2006;113:e684-5.)
94. The CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
95. Hjalmarson A, Goldstein S, Fagerberg B, et al, for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302.
96. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
97. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. β-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288: 351-7.
98. Waal HJ. Propranolol-induced depression [letter]. Br Med J 1967;2:50.
99. Sinha S, Goldstein M, Penrod J, et al. Brief report: β-blocker use among veterans with systolic heart failure. J Gen Intern Med 2006;21:1306-9.
100. Gupta R, Tang WH, Young JB. Patterns of β-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J 2004;147:79-83.
101. . Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to β-blocker therapy. Arch Intern Med 1990;150: 2286-90.
102. Prisant LM, Spruill WJ, Fincham JE, Wade WE, Carr AA, Adams MA. Depression associated with antihypertensive drugs. J Fam Pract 1991;33:481-5.
103. van Melle JP, de Jonge P, Kuyper AM, et al. Prediction of depressive disorder following myocardial infarction data from the myocardial infarction and depression-intervention trial (MIND-IT). IntJ Cardiol 2006;109:88-94.
104. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005;58:175-89.
105. U.S. National Institute of Health. ClinicalTrials.gov. Available from www.clinicaltrials.gov. Accessed April 15, 2008.